MedPath

Prediction of the Response to a Course of Transcranial Magnetic Stimulation (rTMS) Based on Heart Rate Variability

Suspended
Conditions
Major Depressive Disorder
Interventions
Device: repetitive transcranial magnetic stimulation
Registration Number
NCT06451809
Lead Sponsor
GCS CIPS
Brief Summary

Changes in heart rate variability following a single session of rTMS will be tested as a predictor of response to a course of 30 rTMS sessions in patients with major depressive disorder (MDD).

Detailed Description

The objective of this study is to investigate whether acute changes in heart rate variability following a single session of repetitive transcranial magnetic stimulation (rTMS) can predict the response to a 30-session course of rTMS in patients with major depressive disorder (MDD) with good sensitivity and specificity. Patients who are prescribed rTMS to treat an episode of MDD at one of the nine participating centres will be invited to participate in the study. The protocol includes one inclusion visit and seven evaluation visits before, during, and after the course of rTMS. The rTMS course will last for six weeks, comprising of 30 sessions with five sessions per week. Prior to the start of the rTMS course, the patient will have to fill in a number of questionnaires. Before the first session, heart rate variability will be assessed by recording the RR interval at rest using a heart rate belt on the armchair stimulation. A second RR interval recording will be taken immediately after the first rTMS session. Patients will answer questionnaires weekly and after the final rTMS session to track the progression of depressive symptoms.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Having a prescription for a course of rTMS to treat an episod of MDD
  • Unipolar MDD confirmed according to DSM-5 criteria
  • Moderate to severe MDD (MADRS score > 19)
  • No use of psychotropic medication or use stabilised (no change in dose < 4 weeks before study entry)
  • Able to understand, speak, read and write French
  • Express informed consent, after a period of reflection
  • Affiliated with a French social security scheme or beneficiary of such a scheme

Exclusion criteria:

  • History of epilepsy or convulsive seizures
  • Previous brain surgery
  • History of recent cranial trauma (< 6 months)
  • Presence of severe suicidal ideation
  • Psychotic disorders
  • Metal objects in the head, eyes or brain
  • Implanted ferromagnetic equipment (pace maker, cochlear implant, etc.)
  • Clinical evidence of serious or uncontrolled alcohol or substance use disorders in the three months prior to the study
  • Active withdrawal from alcohol or other substances
  • One or more recent rTMS sessions (< 4 weeks)
  • Other non-drug therapy recently initiated (< 4 weeks) to treat MDD (psychotherapy, phototherapy, vagus nerve stimulation, etc.)
  • Prescription of cardiotropic drugs belonging to the following classes: predominantly cardiac calcium channel blockers, Vaughan Williams class I anti-arrhythmics and beta-blockers.
  • Subjects in a period of relative exclusion from another protocol
  • Adults protected by law or patients under guardianship or curatorship
  • Subjects deprived of their liberty by judicial or administrative decision
  • Pregnant or breast-feeding women
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with MDDrepetitive transcranial magnetic stimulationPatients who are prescribed a course of 30 rTMS sessions to treat an episode of MDD at one of the nine participating centres
Primary Outcome Measures
NameTimeMethod
Threshold of variation in terms of RMSSD between normal heartbeats enabling to predict the response to the course of rTMS with the best possible sensitivity and specificity.One day for heart rate variability records (Before and after the first rTMS session), and 6 weeks for assessing the MADRS scores (before and after the course of 30 rTMS sessions)

Threshold of variation in terms of RMSSD (root mean square of successive differences) between normal heartbeats after a single rTMS session enabling to predict the response to the course of rTMS with the best possible sensitivity and specificity. The response to the course of rTMS will be assessed via the evolution of the MADRS score (decrease of MADRS score \>50%)

Secondary Outcome Measures
NameTimeMethod
Threshold of variation in heart rate variability markers enabling to predict the remission to the course of rTMS with the best possible sensitivity and specificity.One day for heart rate variability records (Before and after the first rTMS session), and 6 weeks for assessing the MADRS scores (before and after the course of 30 rTMS sessions)

Threshold of variation in heart rate variability markers (RMSSD, SDNN, low frequencies, high frequencies and low to high frequencies ratio) after a single rTMS session enabling to predict the remission to the course of rTMS with the best possible sensitivity and specificity. The remission to the course of rTMS will be assessed via the evolution of the MADRS score (MADRS ≤ 10 after the course of rTMS)

Threshold of other heart rate variability markers enabling to predict the response to the course of rTMS with the best possible sensitivity and specificity.One day for heart rate variability records (Before and after the first rTMS session), and 6 weeks for assessing the MADRS scores (before and after the course of 30 rTMS sessions)

Threshold of variation in other heart rate variability markers (SDNN, low frequencies, high frequencies and low to high frequencies ratio) after a single rTMS session enabling to predict the response to the course of rTMS with the best possible sensitivity and specificity. The response to the course of rTMS will be assessed via the evolution of the MADRS score (decrease of MADRS score \>50%)

Trial Locations

Locations (9)

Clinique Inicea du Pays de Seine

🇫🇷

Bois-le-Roi, France

Clinique Inicea La Mare O Dans

🇫🇷

Les Damps, France

Clinique Inicea Villa des Roses

🇫🇷

Lyon, France

Etablissement public de santé de Ville-Evrard

🇫🇷

Neuilly-sur-Marne, France

Centre médical de psychiatrie NeuroStim Luxembourg

🇫🇷

Paris, France

Centre médical de psychiatrie NeuroStim Etoile

🇫🇷

Paris, France

Clinique Inicea Jeanne d'Arc Hopital Privé Parisien

🇫🇷

Saint-Mandé, France

Centre montois de psychiatrie ambulatoire Inicea

🇫🇷

Saint-Pierre-du-Mont, France

Centre Tourangeau de psychiatrie ambulatoire Inicea

🇫🇷

Tours, France

© Copyright 2025. All Rights Reserved by MedPath